Immuneering Reports Preclinical Support for Atebimetinib Combinations
Immuneering reported preclinical support for atebimetinib combinations in pancreatic cancer.
Related stories
Nooks Secures $500M and Launches AI Sales Assistant Node
M impact | EQUITY | Nov 04, 2026, 02:10 PM UTC
Algoma Central Closes $70 Million Convertible Debenture Financing
Algoma Central closed its previously announced offering of $70 million in 6.20% convertible unsecured subordinated debentures, priced at $1,000 each.
M impact | EQUITY | Nov 04, 2026, 01:55 PM UTC
Algoma Central Closes $90 Million Convertible Debenture Financing
M impact | EQUITY | Nov 04, 2026, 01:55 PM UTC
Seacon Shipping Agrees to Acquire Vessel for $19.60 Million
Seacon Shipping announced a vessel acquisition agreement valued at USD 19.60 million.
M impact | EQUITY | Nov 04, 2026, 01:54 PM UTC
Sequoia Capital to Close London Office, Raises About $10 Billion
M impact | EQUITY | Nov 04, 2026, 01:54 PM UTC
Atlanta Braves Q3 Earnings Fall as Revenue Rises
Atlanta Braves reported lower Q3 earnings and higher revenue.
M impact | EQUITY | Nov 04, 2026, 01:54 PM UTC